================================================================================
JAVELIN.AI - DATA QUALITY EXECUTIVE SUMMARY
Generated: 2026-01-25 23:08:18
================================================================================

OVERVIEW
--------
Total Subjects: 57,997
Total Sites: 3,424
Studies: 23

RISK DISTRIBUTION
-----------------
Subject Level:
  * High Risk: 5,370 subjects (9.3%)
  * Medium Risk: 7,488 subjects (12.9%)
  * Low Risk: 45,139 subjects

Site Level:
  * High Risk Sites: 403 (11.8%)

REGIONAL ANALYSIS
-----------------
  ⚠️ ASIA: 13 countries, 689 sites, 8,504 subjects
     DQI: 0.067 | High-risk rate: 9.5% | vs Portfolio: +33.7%
  ⚠️ EMEA: 49 countries, 1478 sites, 27,514 subjects
     DQI: 0.050 | High-risk rate: 8.7% | vs Portfolio: -0.1%
  ⚠️ AMERICA: 7 countries, 1232 sites, 21,937 subjects
     DQI: 0.042 | High-risk rate: 9.8% | vs Portfolio: -17.2%
  ✓ Unknown: 3 countries, 25 sites, 42 subjects
     DQI: 0.012 | High-risk rate: 2.4% | vs Portfolio: -76.6%

COUNTRIES REQUIRING ATTENTION
-----------------------------
  [CRITICAL] DEU (EMEA): 90 sites, DQI=0.113, High-risk=13.3%
        → URGENT: 41 pending SAE reviews in DEU
  [CRITICAL] ISR (EMEA): 50 sites, DQI=0.097, High-risk=14.1%
        → URGENT: 66 pending SAE reviews in ISR
  [CRITICAL] TUR (EMEA): 59 sites, DQI=0.096, High-risk=9.5%
        → URGENT: 62 pending SAE reviews in TUR
  [CRITICAL] KOR (ASIA): 57 sites, DQI=0.095, High-risk=12.6%
        → URGENT: 84 pending SAE reviews in KOR
  [CRITICAL] AUS (ASIA): 64 sites, DQI=0.095, High-risk=13.5%
        → URGENT: 95 pending SAE reviews in AUS
  [CRITICAL] TWN (ASIA): 45 sites, DQI=0.079, High-risk=9.4%
        → URGENT: 42 pending SAE reviews in TWN
  [CRITICAL] SGP (ASIA): 25 sites, DQI=0.079, High-risk=15.9%
        → URGENT: 34 pending SAE reviews in SGP
  [CRITICAL] GRC (EMEA): 27 sites, DQI=0.078, High-risk=6.4%
        → URGENT: 7 pending SAE reviews in GRC
  [CRITICAL] BEL (EMEA): 35 sites, DQI=0.076, High-risk=19.7%
        → URGENT: 82 pending SAE reviews in BEL
  [CRITICAL] JPN (ASIA): 105 sites, DQI=0.071, High-risk=5.1%
        → URGENT: 9 pending SAE reviews in JPN

AI-GENERATED INSIGHT
--------------------
Executive Summary:

The current clinical trial portfolio encompasses 57,997 subjects across 3424 sites, spanning 23 studies. Notably, 9.3% of subjects exhibit high risk status, with 51 critical sites identified. Key concerns include an outstanding Max Days issue affecting 27,640 records, lab issues totaling 6,846, and a substantial backlog of 6,496 pending serious adverse event (SAE) reviews.

To mitigate these risks, priority actions for this week should focus on expediting the resolution of Max Days outstanding to minimize potential study disruptions. Additionally, addressing lab issues and clearing the backlog of SAE reviews are critical to maintaining data quality and ensuring regulatory compliance. Collaboration with relevant teams is essential to ensure swift progress in these areas. Furthermore, a detailed analysis of critical sites should be conducted to develop remediation plans aimed at improving overall site performance and reducing high-risk subjects.

CRITICAL ITEMS REQUIRING IMMEDIATE ACTION
-----------------------------------------
[!] PENDING SAE REVIEWS: 6496 subjects have SAE records awaiting review
    Action: Immediate pharmacovigilance review required

[!] CRITICAL SUBJECTS: 4531 subjects require immediate intervention
[!] CRITICAL SITES: 51 sites flagged for urgent quality review

TOP PRIORITIES THIS WEEK
------------------------
1. [CRITICAL] Study_1 - Site 17 (ESP)
   DQI Score: 0.516 | High-risk subjects: 2
   AI Insight: Given the critical data quality issue (DQI Score: 0.516) at Site 17 in ESP for Study_1, immediate attention is required to address the identified risks. The top issues include a high number of SAEs pe...

2. [CRITICAL] Study_16 - Site 674 (DEU)
   DQI Score: 0.497 | High-risk subjects: 2
   AI Insight: Given the CRITICAL risk level and DQI score of 0.497 for Site 674 in DEU during Study_16, it is imperative to address the identified issues promptly to maintain data quality. The top issues include pe...

3. [CRITICAL] Study_16 - Site 759 (TUR)
   DQI Score: 0.444 | High-risk subjects: 1
   AI Insight: Given the CRITICAL risk level and DQI score of 0.444 for Site 759 in TUR for Study_16, immediate attention is required. The top issues include a high number of lab issues (41 instances), SAEs pending ...

4. [CRITICAL] Study_1 - Site 4 (FRA)
   DQI Score: 0.346 | High-risk subjects: 2
   AI Insight: Given the CRITICAL DQI score for Site 4 in FRA for Study_1, it is imperative to address the identified issues promptly to ensure data quality. The top priority should be resolving the outstanding SAEs...

5. [CRITICAL] Study_1 - Site 27 (CHN)
   DQI Score: 0.343 | High-risk subjects: 2
   AI Insight: Given the critical data quality issue (DQI Score: 0.343) at Site 27 in CHN for Study_1, it is recommended to prioritize addressing outstanding safety issues (SAE pending count: 40 instances) and missi...


RECOMMENDATIONS BY CATEGORY
---------------------------
* Max Days Outstanding: 27640 instances
  Priority: MEDIUM | Action: Escalate data entry delays to site

* Lab Issues Count: 6846 instances
  Priority: MEDIUM | Action: Reconcile lab data with central lab vendor

* Sae Pending Count: 6496 instances
  Priority: CRITICAL | Action: Immediate SAE review and regulatory submission required

* Inactivated Forms Count: 4049 instances
  Priority: LOW | Action: Review inactivated forms for audit trail compliance

* Missing Pages Count: 3620 instances
  Priority: MEDIUM | Action: Issue data query for missing CRF pages

* Missing Visit Count: 944 instances
  Priority: HIGH | Action: Contact site to schedule missed visits or document reason

* Edrr Open Issues: 599 instances
  Priority: LOW | Action: Resolve external data reconciliation discrepancies

* Uncoded Whodd Count: 434 instances
  Priority: LOW | Action: Code medication terms to WHODrug dictionary

* Uncoded Meddra Count: 327 instances
  Priority: HIGH | Action: Code adverse event terms to MedDRA dictionary


================================================================================
